Effectiveness, immunogenicity and safety of monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines: results from two randomized, active-comparator, non-inferiority trials - PubMed
10 hours ago
- #booster effectiveness
- #COVID-19 vaccines
- #clinical trial
- Monovalent DS-5670a and bivalent DS-5670a/b SARS-CoV-2 vaccines were tested as boosters in two randomized trials.
- DS-5670 vaccines use lipid nanoparticle-mRNA platform with RBD-derived antigens from original and Omicron strains.
- Both vaccine compositions met non-inferiority criteria compared to existing vaccines (BNT162b2, mRNA-1273).
- DS-5670 showed effective immune responses and broad neutralization across Omicron sub-lineages.
- No serious adverse events were associated with DS-5670 in either study.
- The platform is suitable for seasonal boosters and adaptable to future SARS-CoV-2 variants.